Pharmacological basis and clinical evidence of dabigatran therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : Biomed Central, 2008-
    • Subject Terms:
      Anticoagulants/*pharmacology ; Benzimidazoles/*pharmacology ; beta-Alanine/*analogs & derivatives; Anticoagulants/pharmacokinetics ; Anticoagulants/therapeutic use ; Atrial Fibrillation/drug therapy ; Benzimidazoles/pharmacokinetics ; Benzimidazoles/therapeutic use ; Dabigatran ; Humans ; Kidney Failure, Chronic/drug therapy ; Thrombosis/drug therapy ; beta-Alanine/pharmacokinetics ; beta-Alanine/pharmacology ; beta-Alanine/therapeutic use
    • Abstract:
      Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. It has been approved in the European Union and the United States of America for the prevention of thrombosis after major orthopedic surgery. It has also been approved by the American Food and Drug Administration and the European Medicines Agency for the prevention of stroke in chronic atrial fibrillation. Dabigatran provides a stable anticoagulation effect without any need to perform periodical laboratory controls. Of note, there is a growing amount of clinical evidence which shows its safety and efficacy. For these reasons, dabigatran may suppose a revolution in oral anticoagulation. However, two important limitations remain. First, it is contraindicated in patients with end-stage renal disease. Second, there is no evidence of the prevention of thrombosis in mechanical heart valves.
    • References:
      N Engl J Med. 2009 Dec 10;361(24):2342-52. (PMID: 19966341)
      Br J Clin Pharmacol. 2007 Sep;64(3):292-303. (PMID: 17506785)
      J Thromb Haemost. 2005 Jan;3(1):103-11. (PMID: 15634273)
      Thromb Haemost. 2010 Jun;103(6):1116-27. (PMID: 20352166)
      Clin Pharmacokinet. 2010 Apr;49(4):259-68. (PMID: 20214409)
      J Med Toxicol. 2011 Dec;7(4):281-7. (PMID: 21887485)
      Thromb Res. 2010 Sep;126(3):175-82. (PMID: 20434759)
      Blood. 2010 Jan 7;115(1):15-20. (PMID: 19880491)
      Clin Pharmacokinet. 2008;47(5):285-95. (PMID: 18399711)
      J Arthroplasty. 2009 Jan;24(1):1-9. (PMID: 18534438)
      Circulation. 2011 Oct 4;124(14):1573-9. (PMID: 21900088)
      Lancet. 2007 Sep 15;370(9591):949-56. (PMID: 17869635)
      J Thromb Haemost. 2007 Nov;5(11):2178-85. (PMID: 17764540)
      Thromb Haemost. 2007 Jul;98(1):155-62. (PMID: 17598008)
      Lancet. 2003 Sep 6;362(9386):789-97. (PMID: 13678873)
      Am J Cardiol. 2007 Nov 1;100(9):1419-26. (PMID: 17950801)
      J Am Coll Cardiol. 2011 Mar 15;57(11):1330-7. (PMID: 21324629)
      N Engl J Med. 2009 Sep 17;361(12):1139-51. (PMID: 19717844)
      J Thromb Haemost. 2004 Sep;2(9):1573-80. (PMID: 15333033)
    • Accession Number:
      0 (Anticoagulants)
      0 (Benzimidazoles)
      11P2JDE17B (beta-Alanine)
      I0VM4M70GC (Dabigatran)
    • Publication Date:
      Date Created: 20111223 Date Completed: 20120523 Latest Revision: 20211021
    • Publication Date:
      20231215
    • Accession Number:
      PMC3262761
    • Accession Number:
      10.1186/1756-8722-4-53
    • Accession Number:
      22189016